[Hepatotoxicity of tyrosine kinase inhibitors: Mechanisms involved and practical implications]. / Toxicité hépatique des inhibiteurs des tyrosines kinases : mécanismes en cause et conséquences pratiques.
Bull Cancer
; 105(3): 290-298, 2018 Mar.
Article
en Fr
| MEDLINE
| ID: mdl-29471963
ABSTRACT
Tyrosine kinase inhibitors (TKIs) are used for the targeted treatment of solid cancers. TKIs produce a variable incidence of liver adverse events (5-25%) which can progress to severe liver injury in a minority of patients if treatment is maintained despite ongoing injury. This risk requires careful patient management to maintain treatment benefit without harm. This review highlights the various mechanisms of idiosyncratic hepatotoxicity, the formation of reactive metabolites and how this leads to toxicity. These critical events depend of the drug-specific characteristics of each TKI and the patient risk factors, especially genetic characterization. With improved understanding of the mechanisms leading to hepatotoxicity, several strategies have been adopted to prevent or treat this side effect. Recommendations on liver function liver test monitoring have been proposed according to each TKI.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Inhibidores de Proteínas Quinasas
/
Enfermedad Hepática Inducida por Sustancias y Drogas
/
Hígado
Tipo de estudio:
Guideline
/
Risk_factors_studies
Límite:
Humans
Idioma:
Fr
Revista:
Bull Cancer
Año:
2018
Tipo del documento:
Article